The potential of positron-emission tomography to study anticancer-drug resistance

被引：24

作者：

West, CML

Jones, T

Price, P

机构：

[1] Univ Manchester, Christie Hosp NHS Trust, Acad Dept Radiat Oncol, Manchester M20 4BX, Lancs, England

[2] Univ Manchester, Christie Hosp NHS Trust, Manchester Mol Imaging Ctr, Manchester M20 4BX, Lancs, England

来源：

NATURE REVIEWS CANCER | 2004年 / 4卷 / 06期

关键词：

D O I：

10.1038/nrc1368

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Positron-emission tomography (PET) is a powerful tool for imaging and quantifying cellular and molecular processes in humans. It has enormous potential to increase our understanding of the pathophysiology of human tumours and to support the development of anticancer drugs. The ability of PET to image mechanisms of anticancer-drug resistance in vivo should be exploited in proof-of-concept studies at early stages of drug development.

引用

页码：457 / 469

页数：13

共 142 条

[1]

Aboagye EO, 2001, CANCER RES, V61, P4937

[2]

Aleksic S, 2001, J NUCL MED, V42, P1274

[3] Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane [J].